Color
Text Size
05/03/2023
Thea Portfolio of Products Acquired from Akorn are not Affected by this Recall
WALTHAM, Mass., April 28, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development, and commercialization of ophthalmic products, is responding to the recent statement related to the Akorn Operating Company LLC (“Akorn”) voluntary nationwide recall. On April 26, 2023, the Akorn Trustee issued a company announcement that initiated a voluntary recall of various within-expiry human and animal products as a result of its U.S. facility closures and discontinuation of the Quality activities of these marketed products.
Akorn’s recall announcement has raised questions related to the Thea portfolio of products, AcellFX™, Akten®, AzaSite®, Betimol®, Cosopt®, Cosopt® PF, and Zioptan® acquired last year from Akorn. These Thea products are not impacted by Akorn’s recall. None of these products are manufactured at Akorn’s U.S. facilities that have been closed.
For your reference, the Thea portfolio of products is described in the table below. Note that the Akorn and new Thea labeled versions of these products are equivalent and are both unaffected by the Akorn voluntary recall.
|
Thea Product Descriptions |
Thea |
Akorn |
|
Akten® (lidocaine hydrochloride ophthalmic gel) 3.5% |
82584-792-01 82584-792-25 |
17478-792-01 17478-792-25 |
|
AzaSite (azithromycin ophthalmic solution) 1% sterile |
82584-307-02 82584-307-03 |
17478-307-03 |
|
Betimol® (timolol ophthalmic solution) 0.25%, 0.5% |
82584-001-05 82584-002-05 82584-002-15 |
76478-001-05 76478-002-05 76478-002-15 |
|
Cosopt® (dorzolamide hydrochloride-timolol maleate |
82584-605-10 |
17478-605-10 |
|
Cosopt® PF (dorzolamide hydrochloride-timolol maleate |
82584-604-30 |
17478-604-30 |
|
Zioptan® (tafluprost ophthalmic solution) 0.0015% |
82584-609-30 |
17478-609-10 17478-609-30 |
About Théa
Laboratoires Théa is an independent pharmaceutical company specialized in the research, development, and commercialization of eye-care products. Based in Clermont-Ferrand, France, it has thirty-five affiliates & offices in Europe, North and South America, North Africa, and the Middle East. Today, its network includes more than 1,600 employees, and its products are available in 75 countries around the world. In 2021, Théa had global revenues of approximately $773 million. The independent and family-owned and run group, founded from a Research and Development start-up by Henri Chibret, has been chaired since 2008 by Jean-Frédéric Chibret, his nephew.
To learn more about Laboratoires Théa Group, visit https://www.laboratoires-thea.com/en/Group
About Thea Pharma Inc.
Established in Lexington, Massachusetts in 2019, Thea Pharma Inc., is the United States fully owned subsidiary of Laboratoires Théa. Its product offering is comprised of a portfolio of leading eye-care products that are regulated or approved by the U.S. Food and Drug Administration (FDA), including AcellFX™, Akten®, AzaSite®, Betimol®, Cosopt®, Cosopt® PF, and Zioptan®, iVIZIA® dry-eye drops and eyelid hygiene products, and now IYUZEH™. By focusing our passion and expertise within the U.S. market, Thea’s goal is to deliver uncompromising care that allows all stakeholders to envision the future of ophthalmic treatment with eyes wide open.
To learn more about Thea Pharma Inc., visit https://theapharmainc.com.
SOURCE Thea Pharma Inc.
IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA), is now available in the U.S.
05/31/2023
The Glaucoma Foundation, The Intrepid Eye Society, National Medical Association Ophthalmology Section, and Real World Ophthalmology Unite with Thea to Help Preserve Patient Eye Health WALTHAM, Mass., May 30, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent ophthalmic-focused pharmaceutical company, Laboratoires Théa, today announced the launch of the Preservative Freedom Coalition to raise awareness of unmet […]
LEXINGTON, Massachusetts – March 3, 2023 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Théa, dedicated to the research, development, and commercialization of ophthalmic products, announced the presentation of Phase III data on IYUZEH (latanoprost ophthalmic solution) 0.005% by Jason Bacharach, MD at the 2023 American Glaucoma Society (AGS) […]
IYUZEH™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LEXINGTON, Massachusetts – December 14, 2022 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development and commercialization of ophthalmic products, […]
Théa Pharma announced the availability of the iVIZIA line of over-the-counter (OTC) eye care products in the United States. The iVIZIA OTC product line includes lubricating eye drops, lubricating eye gel, and three options for daily hygiene of sensitive eyelids. iVIZIA eye drops offer preservative-free extended relief and ocular surface protection to patients with any type of […]
LEXINGTON, MASSACHUSETTS – March 9, 2022 – Théa Pharma Inc. (“Théa”), the US subsidiary of Europe’s leading independent pharmaceutical company specializing in the research, development and commercialization of eye care products, today announced the completion of its previously announced acquisition of seven branded ophthalmic products from Akorn Operating Company LLC. The transaction expands Théa’s role […]
CLERMONT-FERRAND, FRANCE – January 28, 2022 – Laboratoires Théa SAS (“Théa”), Europe’s leading independent pharmaceutical company specializing in the research, development, and commercialization of eye-care products, today announced an agreement to purchase seven branded ophthalmic products from Akorn Operating Company LLC. The transaction will make Théa a best-in-class provider of products designed to fill the […]
Théa, the leading European pharmaceutical group in ophthalmology (excluding the retina market), increases its research and clinical trials capacity by doubling its innovation space footprint at the headquarters in Clermont-Ferrand.
03/07/2021
World Glaucoma Week (March 7-13) is a global initiative of the World Glaucoma Association (WGA) to raise awareness on glaucoma. Glaucoma is a chronic eye disease that has become the 2nd leading cause of blindness in the world.
The Théa Group has announced the appointment of Ms. Susan Benton as Country Manager for the US entity, Thea Pharma Inc. Ms. Benton is a senior executive with more than 25 years of global commercial and business development experience in ophthalmic pharmaceuticals.